760 related articles for article (PubMed ID: 17205957)
21. Role of matrix metalloproteinases 1, 2, and 9 and tissue inhibitor of matrix metalloproteinase-1 in chronic venous insufficiency.
Saito S; Trovato MJ; You R; Lal BK; Fasehun F; Padberg FT; Hobson RW; Durán WN; Pappas PJ
J Vasc Surg; 2001 Nov; 34(5):930-8. PubMed ID: 11700497
[TBL] [Abstract][Full Text] [Related]
22. Combined effects of moderately elevated blood glucose and locally produced TGF-beta1 on glomerular morphology and renal collagen production.
Krag S; Nyengaard JR; Wogensen L
Nephrol Dial Transplant; 2007 Sep; 22(9):2485-96. PubMed ID: 17452404
[TBL] [Abstract][Full Text] [Related]
23. Different circulating metalloproteinases profiles in women with migraine with and without aura.
Martins-Oliveira A; Speciali JG; Dach F; Marcaccini AM; Gonçalves FM; Gerlach RF; Tanus-Santos JE
Clin Chim Acta; 2009 Oct; 408(1-2):60-4. PubMed ID: 19627981
[TBL] [Abstract][Full Text] [Related]
24. [Metalloproteinases MMP-2 and MMP-9 and their inhibitors TIMP-1 and TIMP-2 levels in children and adolescents with type 1 diabetes].
Florys B; Głowińska B; Urban M; Peczyńska J
Endokrynol Diabetol Chor Przemiany Materii Wieku Rozw; 2006; 12(3):184-9. PubMed ID: 17020653
[TBL] [Abstract][Full Text] [Related]
25. Matrix metalloproteinases in premature coronary atherosclerosis: influence of inhibitors, inflammation, and genetic polymorphisms.
Nanni S; Melandri G; Hanemaaijer R; Cervi V; Tomasi L; Altimari A; Van Lent N; Tricoci P; Bacchi L; Branzi A
Transl Res; 2007 Mar; 149(3):137-44. PubMed ID: 17320799
[TBL] [Abstract][Full Text] [Related]
26. [The effects of endothelin-1 and selective endothelin receptor-type A antagonist on human renal interstitial fibroblasts in vitro].
Tian X; Tang G; Chen Y
Zhonghua Yi Xue Za Zhi; 2002 Jan; 82(1):5-9. PubMed ID: 11953117
[TBL] [Abstract][Full Text] [Related]
27. Matrix metalloproteinases/tissue inhibitors of metalloproteinases: relationship between changes in proteolytic determinants of matrix composition and structural, functional, and clinical manifestations of hypertensive heart disease.
Ahmed SH; Clark LL; Pennington WR; Webb CS; Bonnema DD; Leonardi AH; McClure CD; Spinale FG; Zile MR
Circulation; 2006 May; 113(17):2089-96. PubMed ID: 16636176
[TBL] [Abstract][Full Text] [Related]
28. [Involvement of matrix metalloproteinases in the regulation of myocardial extracellular matrix in patients with congestive heart failure].
Yang YJ; Zhang X; Zhu WL; Huang Y
Zhonghua Yi Xue Za Zhi; 2006 Jun; 86(24):1693-6. PubMed ID: 16854324
[TBL] [Abstract][Full Text] [Related]
29. Circulating matrix metalloproteinase-2 but not matrix metalloproteinase-3, matrix metalloproteinase-9, or tissue inhibitor of metalloproteinase-1 predicts outcome in patients with congestive heart failure.
George J; Patal S; Wexler D; Roth A; Sheps D; Keren G
Am Heart J; 2005 Sep; 150(3):484-7. PubMed ID: 16169329
[TBL] [Abstract][Full Text] [Related]
30. Upregulation of tissue inhibitor of metalloproteases-1 (TIMP-1) and procollagen-N-peptidase in hypertension-induced renal damage.
Hultström M; Leh S; Skogstrand T; Iversen BM
Nephrol Dial Transplant; 2008 Mar; 23(3):896-903. PubMed ID: 17977875
[TBL] [Abstract][Full Text] [Related]
31. Significant increases in serum and plasma concentrations of matrix metalloproteinases 3 and 9 in patients with rapidly destructive osteoarthritis of the hip.
Masuhara K; Nakai T; Yamaguchi K; Yamasaki S; Sasaguri Y
Arthritis Rheum; 2002 Oct; 46(10):2625-31. PubMed ID: 12384920
[TBL] [Abstract][Full Text] [Related]
32. Assessment of matrix metalloproteinase (MMP)-2, MMP-8, MMP-9, and their inhibitors, the tissue inhibitors of metalloproteinase (TIMP)-1 and TIMP-2 in obese children and adolescents.
Belo VA; Souza-Costa DC; Lana CM; Caputo FL; Marcaccini AM; Gerlach RF; Bastos MG; Tanus-Santos JE
Clin Biochem; 2009 Jul; 42(10-11):984-90. PubMed ID: 19358835
[TBL] [Abstract][Full Text] [Related]
33. Relation of matrix metalloproteinase-9/tissue inhibitor of metalloproteinase-1 ratio in peripheral circulating CD14+ monocytes to progression of coronary artery disease.
Brunner S; Kim JO; Methe H
Am J Cardiol; 2010 Feb; 105(4):429-34. PubMed ID: 20152234
[TBL] [Abstract][Full Text] [Related]
34. MMPs, TIMP-2, and TGF-beta1 in the cancerization of oral lichen planus.
Chen Y; Zhang W; Geng N; Tian K; Jack Windsor L
Head Neck; 2008 Sep; 30(9):1237-45. PubMed ID: 18642282
[TBL] [Abstract][Full Text] [Related]
35. Matrix metalloproteinase-2, -9, and tissue inhibitor of metalloproteinase-1 in patients with hypertension.
Derosa G; D'Angelo A; Ciccarelli L; Piccinni MN; Pricolo F; Salvadeo S; Montagna L; Gravina A; Ferrari I; Galli S; Paniga S; Tinelli C; Cicero AF
Endothelium; 2006; 13(3):227-31. PubMed ID: 16840178
[TBL] [Abstract][Full Text] [Related]
36. Alterations in peripheral blood levels of TIMP-1, MMP-2, and MMP-9 in patients with type-2 diabetes.
Lee SW; Song KE; Shin DS; Ahn SM; Ha ES; Kim DJ; Nam MS; Lee KW
Diabetes Res Clin Pract; 2005 Aug; 69(2):175-9. PubMed ID: 16005367
[TBL] [Abstract][Full Text] [Related]
37. Occurrence of matrix metalloproteinases and tissue inhibitors of metalloproteinases in tuberculous pleuritis.
Hoheisel G; Sack U; Hui DS; Huse K; Chan KS; Chan KK; Hartwig K; Schuster E; Scholz GH; Schauer J
Tuberculosis (Edinb); 2001; 81(3):203-9. PubMed ID: 11466032
[TBL] [Abstract][Full Text] [Related]
38. Basement membrane remodeling in skeletal muscles of patients with limb ischemia involves regulation of matrix metalloproteinases and tissue inhibitor of matrix metalloproteinases.
Baum O; Ganster M; Baumgartner I; Nieselt K; Djonov V
J Vasc Res; 2007; 44(3):202-13. PubMed ID: 17337906
[TBL] [Abstract][Full Text] [Related]
39. Angiotensin-II and rosuvastatin influence matrix remodeling in human mesangial cells via metalloproteinase modulation.
Solini A; Rossi C; Santini E; Madec S; Salvati A; Ferrannini E
J Hypertens; 2011 Oct; 29(10):1930-9. PubMed ID: 21881526
[TBL] [Abstract][Full Text] [Related]
40. Imbalanced matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 activities in patients with thromboangiitis obliterans.
Dellalibera-Joviliano R; Jacob-Ferreira AL; Joviliano EE; Tanus-Santos JE; Evora PR
Vasc Med; 2012 Apr; 17(2):73-8. PubMed ID: 22402936
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]